Comparative Cost-Benefit Analyses of Paricalcitol and Calcitriol in Stage 4 Chronic Kidney Disease from the Perspective of a Health Plan

Author： Gal-Moscovici Anca

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.27, Iss.2, 2007-01, pp. : 105-113

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and tolerability of paricalcitol in patients with chronic kidney disease

By Dyer Christopher A

Expert Opinion on Drug Safety, Vol. 12, Iss. 5, 2013-09 ,pp. : 717-728

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK: A Chronic Kidney Disease Markov Model

By Nuijten Mark

Clinical Drug Investigation, Vol. 30, Iss. 8, 2010-08 ,pp. : 545-557

Adis International

Access to resources Recommend Favorite

Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease

By Cheng Steven Coyne Daniel

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 5, 2006-04 ,pp. : 617-621

Informa Healthcare

Access to resources Recommend Favorite

Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children: Theoretical and Methodological Considerations

By Prosser Lisa A.

PharmacoEconomics, Vol. 25, Iss. 9, 2007-01 ,pp. : 713-726

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease

By Brophy Donald F Ripley Elizabeth BD Holdford David A

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 9, 2003-09 ,pp. : 1461-1469

Informa Healthcare

Access to resources Recommend Favorite